CKD-FIX

ckd-fix-logo-2016

A randomised Controlled trial of slowing of Kidney Disease progression From the Inhibition of Xanthine oxidase

Principal Investigator: Professor David Johnson
Clinical Project Manager: Laura Robison (AKTN)
Trial Number: AKTN 10.02

Population: Adults with CKD stage 3/4 and progression of CKD in past 12 months
Intervention: Allopurinol (100-300mg) vs placebo, daily
Follow-up: 24 months
Primary outcome: Change in eGFR
Status: Australian and New Zealand sites currently recruiting
Recruitment end date: 31 December 2016
Follow-up end date: December 2018
Recruitment: 369/620 (49.35%)


Trial Summary:

Chronic kidney disease (CKD) is a major public health problem affecting over 1.5 million Australians and is associated with increased risk of death, heart disease and progression to end-stage kidney disease (ESKD). Current treatments to slow progression to ESKD are limited. The CKD-FIX trial aims to find out whether treatment with allopurinol, a commonly used drug for gout prevention, safely and effectively slows CKD progression. This could lead to significant health and economic benefits.